GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » Asset Turnover

DermTech (DermTech) Asset Turnover : 0.03 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is DermTech Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. DermTech's Revenue for the three months ended in Mar. 2024 was $3.85 Mil. DermTech's Total Assets for the quarter that ended in Mar. 2024 was $112.45 Mil. Therefore, DermTech's Asset Turnover for the quarter that ended in Mar. 2024 was 0.03.

Asset Turnover is linked to ROE % through Du Pont Formula. DermTech's annualized ROE % for the quarter that ended in Mar. 2024 was -164.74%. It is also linked to ROA % through Du Pont Formula. DermTech's annualized ROA % for the quarter that ended in Mar. 2024 was -71.18%.


DermTech Asset Turnover Historical Data

The historical data trend for DermTech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech Asset Turnover Chart

DermTech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - 0.14 0.07 0.06 0.09

DermTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.03 0.03 0.03

Competitive Comparison of DermTech's Asset Turnover

For the Diagnostics & Research subindustry, DermTech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DermTech's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where DermTech's Asset Turnover falls into.



DermTech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

DermTech's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=15.296/( (202.075+121.93)/ 2 )
=15.296/162.0025
=0.09

DermTech's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=3.845/( (121.93+102.97)/ 2 )
=3.845/112.45
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


DermTech  (NAS:DMTK) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

DermTech's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-80.04/48.5845
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-80.04 / 15.38)*(15.38 / 112.45)*(112.45/ 48.5845)
=Net Margin %*Asset Turnover*Equity Multiplier
=-520.42 %*0.1368*2.3145
=ROA %*Equity Multiplier
=-71.18 %*2.3145
=-164.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

DermTech's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-80.04/112.45
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-80.04 / 15.38)*(15.38 / 112.45)
=Net Margin %*Asset Turnover
=-520.42 %*0.1368
=-71.18 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


DermTech Asset Turnover Related Terms

Thank you for viewing the detailed overview of DermTech's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


DermTech (DermTech) Business Description

Traded in Other Exchanges
N/A
Address
11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
Executives
Kevin M Sun officer: Chief Financial Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra officer: Chief Operating Officer C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan officer: General Counsel C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard officer: Chief Commercial Officer 19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood officer: Chief Commercial Officer C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen director, officer: Chief Executive Officer 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak director, officer: Chief Executive Officer 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman director OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037

DermTech (DermTech) Headlines

From GuruFocus